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Abstract
Lungmucociliaryclearance isimpairedin stable asthma.The long-acting b2-agonist salmeterolhasbeen showninvitroto
cause a significant increase in ciliary beat frequency.It seemedpossible therefore that salmeterolmay also have a favour-
able effect on lungmucociliary transport in asthmatic patients.Fourteen patientswith asthma participated in a double-
blind, placebo-controlled, crossover study to assess the effectof 2 weeks of treatment with salmeterol MDI (50 mg b.d.)
onlungmucociliaryclearance.The11patientswhocompletedthe study (sevenmales, four females) hadamean7 SEageof
5074 years, % predicted FEV1of 7478 % and a tobacco consumption history of1377 pack-years (seven non-smokers,
four exsmokers). Lung mucociliary transport was measured by a radioaerosol technique. Pulmonary function indices
(FEV1,FVC, and PEF) were significantly improved on salmeterol relative to placebo.Themain radioaerosol findingwas a
significantincreaseinthepenetrationofradioaerosolintothelungwith 24-hradioaerosolrising from 4075% onplacebo
to 4974% (Po0.01) on salmeterol.Despite this increased penetration, a slight favourable change occurred in tracheo-
bronchial aerosol clearance.This study demonstrates that 2 weeks salmeterol treatment influences deposition of parti-
cles within the lung by increasing airway patency and indicates a beneficial effect of MDI salmeterol on lungmucociliary
clearance.r2003 Elsevier Science Ltd.Allrights reserved.
doi:10.1053/rmed.2003.1498, available online athttp://www.sciencedirect.com
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Asthma is a disease characterised by reversible airway
obstruction caused by mucosal oedema, bronchial
smoothmuscle contraction andhypersecretion ofmucus
(1).Death fromciliary insu⁄ciency andmucus plugging of
small airways in asthmatic patients has been known for
many years (2).
Lung mucociliary clearance is impaired in patients
with mild stable asthma (3) and during acute exacerba-
tion of their disease (4). It has also been shown that lung
mucociliary clearance in asthmatic patients is signi¢-
cantly impaired even during remission (5). Enhancement
of a depressed lungmucociliary clearance can considered
to be of bene¢t as reducing the residence time of bron-
chial secretions should lessen the riskof chest infections (6).
A bronchodilator is extensively used by asthmatic
patients for the relief of their bronchospasm. If such a
drug is shown also to enhance clearance of secretions
then this would be considered as an additional bene¢cialReceived10 June 2002, accepted in revised form 4 November 2002
Correspondence should be addressed to.Dr. A.Hasani,Department of
Medical physics, Royal free Hospital, London NW3 2QG.Fax: 0207-
4331621. E-mail: thoracic.rfh@virgin.nete¡ect of the drug. Salbutamol has been shown to en-
hance lung mucociliary clearance when given topically
from a metered dose inhaler albeit at 2.5 times the nor-
mal recommendeddose (7). Such enhancementofmucus
transport can be due to a direct stimulatory action on
ciliarybeat frequency. Salbutamol has been shown in vitro
to have such stimulatory e¡ect (8).This may in vivo con-
tribute to reducing small airways obstruction andmucus
plugging.
Salmeterol xinafoate is a long-acting b2 adrenoceptor
agonist (9). The bronchodilator e¡ect of single doses of
salmeterol, when compared with cumulative doses of
salbutamol, in patients with asthma was 8^10 times
more potent (10). For systemic e¡ects, salmeterol was
7^17 timesmore potent than salbutamol (11).
The relative e¡ects of salmeterol and salbutamol, in a
time- and dose-dependent manner, on ciliary beat fre-
quency have been compared in vitro (12). Salmeterol was
shown to be maximally active at a very low concentra-
tion of 106M and caused a signi¢cantly rapid and pro-
longed increase in ciliary beat frequency. In contrast
salbutamol was optimally active at a concentration of
104 M and caused a transient but signi¢cant increase in
ciliary beat frequency.
668 RESPIRATORYMEDICINEThe purpose of the present study was to investigate
the e¡ect of salmeterol xinafoate administered from a
MDI, on lung mucociliary clearance in patients with
mild-to moderate stable asthma.
METHODS
Patients
Fourteen volunteer patients (nine men, ¢ve women)
with asthma from our outpatient clinics were studied.
The diagnosis of asthma was based on clinical criteria
(13). Each patient entered into the study after showing
an increase in his/her forced expiratory volume in 1s
(FEV1) of 15% or more following inhalation of 200mg of
salbutamol. Patients on oral b2-agonist drugs and corti-
costeroid therapy were not entered into the study. All
patients had been free of symptoms of respiratory tract
infection for at least 4 weeks before study commence-
ment.Three (twomen) werewithdrawn, two had angina
(during the salmeterol period), and the third because he
was unable to manage without ‘salmeterol’ or additional
bronchodilator therapy during the placebo period.
Thepatientswho completed the studyhad amean7SE
age and height of 5074 years and 1.6970.01m, respec-
tively. Seven patients were lifelong non-smokers and the
remaining four patients were ex-smokers with a
mean7SE tobacco consumption of1377 pack years.The
mean7SE of their percentage predicted FEV1, FVC, and
PEFwere 7478%,9475%, and 9777%, respectively. All
11 patients were receiving treatment with inhaled b2-
agonists, nine were also taking inhaled corticosteroid
drugs. Three of the patients were also receiving treat-
mentwith long-actingbronchodilator,whichwas discon-
tinued at the start of the study.
STUDYDESIGN
The study was designed in a controlled, double-blind,
and crossover (within patients)manner.Patientswere al-
located randomly to receive either salmeterol xinafoate
(2 pu¡s b.d.; 25mg per pu¡) or placebo from metered
dose inhalers. Randomisation was arranged so that half
the patients should receive salmeterol ¢rst.The patients
were instructed to use the trial inhaler for 2 weeks and
at the end of this period their mucociliary clearance and
lung function were assessed.The treatments were then
crossed over and after a further period of 2 weeks a sec-
ond assessment was carried out. The two assessments
were identical in all respects.
This study was not designed to assess the bronchodi-
lator e¡ectof salmeterol.Thepatientswere therefore al-
lowed to take their regular (maintenance) treatment of
inhaled b2-agonists and corticosteroids drugs through-
out the study recording on diary cards the number of
pu¡s taken daily of their usual b2-agonist inhaler. Inhaledb2-agonist drugs were withheld for the 6h preceding
each assessmentday and for the 6h -periodduringwhich
lung mucociliary clearance measurement was made to
avoid any in£uence onmucociliary function.
The study was approved by the ethics committee of
the Royal Free Hospital and informed, written consent
was obtained fromeach patientprior to commencement
of study.
MUCOCILIARYCLEARANCE
Lung mucociliary clearance was measured using an ob-
jective non-invasive radioaerosol technique. Polystyrene
particles (5mm in diameter), ¢rmly labelled with the
radionuclide technetium (99mTc), were inhaledby the vo-
lunteer patients under strictly controlled conditions (14).
Inspiratory £ow rate of the radioaerosol particles was
measured by a pneumotachygraph.
The initial radioaerosol lung depositionwasmeasured
and its subsequent clearance was monitored by two sui-
tably collimated scintillation counters (15). A count was
made immediately following the radioaerosol inhalation
to ascertain the initial whole lung burden. Thereafter,
counts were made at half-hourly intervals for 6h and a
¢nal countwasmade at 24h post-inhalation.The amount
of radioaerosol remaining in the lung at 24 hours was
used to estimate alveolar deposition (AD), (16) which is
the radioaerosol particles deposited in the non-ciliated
airways and was therefore unavailable for mucociliary
clearance. Subtracting the AD from the whole lung
clearance curve yielded a tracheobronchial clearance
curve (17). Tracheobronchial clearance was assessed by
measuring the area under the curve for the 6-h observa-
tion period (AUC0-6).
The initial topographical distribution of the radioaero-
sol within the lungs was assessed by a large ¢eld of view
gamma camera.The radioaerosol distributionwas quan-
titatively expressed in terms of a penetration index (PI)
(18).
Throughout the 6-h observation period all coughs
were recorded and any sputum produced was collected
and its radioactive content expressed as a percentage of
the initial tracheobronchial deposition. This percentage
was added back to the clearance curves to account for
the e¡ect of productive coughing thus yielding a muco-
ciliary clearance curve. (19)
PULMONARYFUNCTION
The pulmonary function of each patient was assessed
before the inhalation of the radioaerosol on each study
day. Forced expiratory volume in one second (FEV1),
forced vital capacity (FVC), and peak expiratory £ow
(PEF) were measured using a Vitalograph spirometer.
The highest value for each pulmonary function index
TABLE 2. Mean7SE radioaerosol inspiratory £owrate,
alveolar deposition (AD), and penetration index (PI) for
the 11 patients following treatment with salmeterol and
placebo.
Placebo Salmeterol P
Flowrate (l/min) 1772 1672 NS
AD (%) 4075 4974 o0.01
P7 0.5770.04 0.7470.02 o0.01
EFFECTOFSALMETEROLONMUCOCILIARYCLEARANCE 669was recorded out of three technically acceptable mea-
surements.
STATISTICALANALYSIS
As the datawere not normally distributed the non-para-
metric Wilcoxon test for paired di¡erences was used.
The level of signi¢cancewas taken as Po0.05.
RESULTS
Six patients received salmeterol treatment ¢rst while
the other ¢ve patients received placebo. The mean7SE
of the percentage predicted pulmonary function indices
for the patients following treatmentwith salmeterol and
placebo are given inTable1.FEV1, FVC, and PEF were sta-
tistically signi¢cantly improved following salmeterol
compared to placebo.
Table 2 gives the mean7SE radioaerosol inspiratory
£ow rate, alveolar deposition and penetration indices
for the two treatments. The radioaerosol was inspired
at a similar £ow rate during the two treatment days,
whereas alveolar deposition and penetration indicesTABLE 1. Mean7SE pulmonary function indices for the
11patients following treatmentwith salmeterolandplace-
bo.
Placebo Salmeterol P
% Pred.FEV1 7378 7678 0.02
% Pred.FVC 9575 10075 0.03
% Pred.PEF 9477 10077 0.04
FIG. 1. Meantracheobronchial clearance curves for11volunteer pwere signi¢cantly increased following treatment with
salmeterol relative to placebo.
The mean tracheobronchial clearance curves for the
salmeterol and placebo treatments were shown in the
¢gure. The tracheobronchial clearance after salmeterol
treatmentwas on average, but not statistically so, faster
when compared to placebo. The mean7SE areas under
the tracheobronchial clearance curves (AUC0-6) were
333724%h after treatment with salmeterol, and
347730%h on placebo.
Four patients had no coughs.However, the number of
coughs and sputum weight produced during the 6-h
observation by the other seven patients was similar
between salmeterol and placebo treatment. The
mean7SE number of coughs was 1574 and 1076; spu-
tum weight was 2.170.8 and 2.671.2 g following treat-
mentwith salmeterol and placebo, respectively.
DISCUSSION
The long acting b2 adrenergic drug salmeterol xinafoate
has been known for some years to have excellent
bronchodilating properties and a demonstrableatients after placebo (~) and salmeterol (*) treatment.
670 RESPIRATORYMEDICINEtherapeutic value in asthma (20,21). Although this study
was not designed to test speci¢cally the bronchodilating
properties of salmeterol, it nevertheless demonstrated
that the addition of this drug resulted in statistically
signi¢cant increases in indices of pulmonary function
over placebo.
Tracheobronchial clearance comprises mucociliary
clearance and cough.Cough has been shown to be very
important clearancemechanism in patients with chronic
airways obstruction (22,23). Since in the 6-h clearance
periods the number of coughs and sputum production
were small and similar after treatment with salmeterol
and placebo, it can be reasonably surmised that any en-
hancement seen in tracheobronchial clearancewould be
attributable to an increase in mucociliary clearance fol-
lowing salmeterol treatment.
Lung mucociliary clearance of deposited radioaerosol
particles depends on the initial distribution of the radio-
aerosol within the lungs (24). If the median or average
deposition depth with the tracheobronchial tree tends
tomove frombronchial to the bronchiolar airways, total
clearance times from the conducting airways are ex-
pectedconsiderable to increase (25). In this study a distal
displacement of deposition sites within the lung certainly
occurred as shown by signi¢cant changes in PI and AD. It
is reasonable to infer that this will have included a distal
shift within the tracheobronchial tree with, speci¢cally,
some shift of deposition from bronchial to bronchiolar
sites.This shift occurred despite theuse of closely similar
aerosol inhalation £ow rates in the two legs of the study
and may reasonable to attributed to the increase in air-
way patency on salmeterol as demonstrated by the im-
provement seen in the pulmonary function data. Yet
despite this likely shift of deposition sites within the con-
ducting airways, tracheobronchial clearance was in fact
slight faster on salmeterol than on placebo.
Our data are thus consistent with salmeterol having a
bene¢cial e¡ect invivo on lungmucus clearance, parallel-
ing its demonstrated e¡ect in vitro on the ciliary beat
frequency of cultured cells (12).
In summary, this studydemonstrates that 2weeks’ sal-
meterol treatment in£uences deposition of particles
within the lung by increasing airway patency and indi-
cates a bene¢cial e¡ect of MDI salmeterol on lungmuco-
ciliary clearance.
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